Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (GB:0HI3)
LSE:0HI3
RESEARCH TOOLSreports
Holding GB:0HI3?
Track your performance easily
0HI3 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.75 - $39.79
Previous Close$23.4
Volume41.00
Average Volume (3M)836.00
Market Cap
$2.99B
Enterprise Value$2.75B
Total Cash (Recent Filing)$367.27M
Total Debt (Recent Filing)$118.09M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Nov 25, 2024EPS Estimate
-$0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.65
Shares Outstanding124,315,274
10 Day Avg. Volume346
30 Day Avg. Volume836
Standard Deviation0.21
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)9.31
Price to Sales (P/S)152.36
Price to Cash Flow (P/CF)-6.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue140.10
Enterprise Value/Gross Profit11.43
Enterprise Value/Ebitda-5.45
Forecast
1Y Price Target
$46.14Price Target Upside97.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Arrowhead Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Pipeline ExpansionExtra-hepatic pipeline expansion shows visible progress with high-value programs like ARO-RAGE, ARO-DM1, ARO-DUX4, and ARO-INHBE.
Positive Clinical DataThe trial met its primary endpoint, with patients treated with 25 and 50 mg doses achieving significant triglyceride reductions compared to the placebo.
Strategic FinancingARWR announced securing $500M strategic financing facility with flexible 7-year repayment structure, which comes timely as management is on the cusp of executing on two key portfolio priorities.
Bears Say
Cholesterol ConcernsPlozasiran treatment led to a rise in LDL cholesterol, which is not a desired treatment outcome even if TGs decrease.
Debt FinancingThe equity sell-off was driven by relatively expensive debt financing coincided with higher than expected R&D spend, which is required to support pipeline candidates' moving into and through clinical trials.
Operational ExpensesOpEx growth has accelerated, sparking debate among investors.
---
Options Prices
Currently, No data available
---
Ownership Overview
9.11% Insiders
23.46% Mutual Funds
48.75% Other Institutional Investors
18.68% Public Companies and
Individual Investors
0HI3 FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest share price was $20.75 and its highest was $39.79 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Currently, no data Available
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is Nov 25, 2024 which is in 85 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Aug 08, 2024. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$0.529 by -$0.851.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -$0.94.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 124,315,280 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -$1.38 in its last earnings report, missing expectations of -$0.529. Following the earnings report the stock price went down -7.225%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Among the largest hedge funds holding Arrowhead Pharmaceuticals’s share is Slate Path Capital LP. It holds Arrowhead Pharmaceuticals’s shares valued at 108M.
---
Arrowhead Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.14 (97.18% Upside)
$46.14 (97.18% Upside)
Blogger Sentiment
Bullish
GB:0HI3 Sentiment 100%
Sector Average 68%
Sector Average 68%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.21%
12-Months-Change
Fundamentals
Return on Equity
-154.92%
Trailing 12-Months
Asset Growth
11.04%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
---
0HI3 Earnings Call
Q3 2024
0:00 / 0:00
---
0HI3 Stock 12 Month Forecast
Average Price Target
$46.14
▲(97.18% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Crispr Therapeutics AG
―
Editas Medicine
―
Arvinas Holding Company
―
Meiragtx Holdings
―
Best Analysts Covering 0HI3
1 Year
1 Year Success Rate
19/36 ratings generated profit
1 Year Average Return
+36.11%
reiterated a buy rating 3 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 52.78% of your transactions generating a profit, with an average return of +36.11% per trade.
---